

**Drugs & Pharmaceuticals witnessing an era of unparalleled growth and innovation,
says MoS Shri Mansukh Mandaviya**

Dated: February 7, 2020

The Union Minister of State for Shipping (I/C) and Chemicals & Fertilizers, Shri Mansukh Mandaviya has said that the Drugs & Pharmaceuticals sector is witnessing an era of unparalleled growth and innovation. “Drugs & Pharmaceuticals are India’s largest sectors-both in terms of revenue and employment,” he said here today.

Keeping in line to attract larger FDI in Pharmaceutical sector, Shri Mandaviya said the government reviews FDI Policy on an ongoing basis with a view to liberalise and simplify the FDI Policy progressively, so as to improve the country’s investment climate by providing ease of doing business. Also, various measures are taken under “Make in India” initiatives facilitating investment, fostering innovation and thereby promoting robust business environment in the country, he added.

In 2015-16, the FDI equity inflows to Drugs and Pharmaceutical Sector was Rs. 4,975 crores. It has increased to Rs.5,723 crores in 2016-17 and further to Rs. 6,502 crores in 2017-18.

The details of FDI equity inflows received in Drugs and Pharmaceutical Sector in the country since 2014 are as under:

S.NO	Financial Year	Total FDI Inflow (Rs. Crores)
1.	2014-15	9,052
2	2015-16	4,975
3	2016-17	5,723
4	2017-18	6,502
5	2018-19	1,842
6	2019-20 (April-September)	2,065

The Government amended the Foreign Direct Investment (FDI) policy on Pharmaceutical sector in June 2016 by allowing 100% FDI for Greenfield Pharmaceutical projects and upto 74% FDI for Brownfield pharmaceutical projects through automatic route and beyond that through government’s approval.

FDI is largely a matter of private business decisions and FDI inflows depend on a host of factors such as availability of natural resource, market size, infrastructure, political and general investment climate as well as macro-economic stability and investment decision of foreign investors.
